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OBJECTIVES This study evaluated the occurrence of prosthesis-patient mismatch (PPM) after Cryolife
O’Brien (CLOB) suprannular stentless valve replacement in patients with a small aortic root
and its repercussions on the patient’s hemodynamic status and left ventricular mass regression.
BACKGROUND The correct management of the small aortic annulus is still controversial. Small aortic
prostheses can lead to a PPM, which results in high gradients with important repercussions
on the hemodynamic status.
METHODS Seventy-two patients (mean age: 72.5  6.2 years, 73.6% women) with a small aortic root
(21 mm intraoperatively measured aortic annulus) had a CLOB valve implanted in the
aortic position between November 1993 and July 2001 at our institution. Mean prosthesis size
was 22.0  0.8 mm. Patients underwent echocardiography preoperatively, at discharge, six
months, one year and yearly thereafter.
RESULTS The incidence of PPM at discharge was 22.2% (16/72); 18.7% were severe (effective orifice
area index [EOAI]0.65 cm/m2), 43.7% were moderate (EOAI 0.66 to 0.75 cm/m2) and
37.6% were mild (0.76 to 0.85 cm/m2). At multivariable analysis, gender (p  0.001), age
(p  0.015), body surface area (p  0.001) and patient’s annulus index (p  0.001) were
significant factors influencing the occurrence of “transient” PPM. At one year the incidence
of PPM was 0%.
CONCLUSIONS Suprannular CLOB valve yielded excellent hemodynamic results in patients with small aortic
roots. This study demonstrates that PPM can be completely avoided when using the CLOB
valve. The superior hemodynamics of this stentless valve are likely to be related to its
suprannular design. (J Am Coll Cardiol 2002;39:1845–51) © 2002 by the American
College of Cardiology Foundation
Patients with small aortic roots undergoing aortic valve
replacement (AVR) present a special challenge to the
surgeon regarding operative technique and selection of
prosthesis. Small aortic annular size has been reported to be
associated with increased operative mortality (1,2). How-
ever, the effects of small aortic prostheses on long-term
survival still remain controversial (3,4). Nevertheless, it is
widely accepted that a discrepancy between the prosthesis
effective orifice area and the patient’s body surface area
(BSA) (prosthesis-patient mismatch [PPM]) (5) results in
abnormally high residual gradients, worsening of the pa-
tient’s hemodynamic status (6,7) and impaired regression of
left ventricular hypertrophy (8). Thus, this condition might
require a reoperation (9).
As conventional stented valves have been demonstrated
to be obstructive and the stent to be a stress factor on the
tissue components (10), stentless valves have no prosthetic
sewing ring and no prosthetic struts and result in larger
effective orifice area (EOA) and lower transvalvular gradi-
ents after AVR (11).
The Cryolife O’Brien bioprosthesis (CLOB) (Cryolife
International, Atlanta, Georgia) is a composite suprannular
stentless valve, which, in our previous reports, yielded good
hemodynamics and significant left ventricular mass (LVM)
regression (12).
The present study was aimed toward evaluating the
occurrence of PPM after CLOB suprannular stentless valve
replacement in patients with a small aortic root and its
repercussions on the patient’s hemodynamic status and
LVM regression.
METHODS
Patients. Between November 1993 and July 2001, 72
consecutive patients with small aortic roots (21 mm
intraoperatively measured aortic annulus) received a CLOB
valve in the aortic position. Mean age was 72.5  6.2 years
(range: 50 to 87 years). Forty patients (55.5%) were over 65
years of age. Nineteen patients (26.4%) were men and 53
(73.6%) women; mean BSA was 1.68  0.8 m2 (range: 1.3
to 2.1 m2); 21 patients (29.2%) were in New York Heart
Association (NYHA) functional class IV, 46 (63.9%) were
in class III and 5 patients (6.9%) were in class II. Mean
preoperative NYHA was 3.2  0.3. Valve pathology con-
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sisted of aortic stenosis in 45 (62.5%) patients, insufficiency
in 8 (11.1%) patients and mixed lesions in 19 (26.4%)
patients. Etiology was degenerative calcific disease in 52
(72.2%) patients, congenital bicuspid valve in 12 (6.7%)
patients, rheumatic disease in 2 (2.8%) patients, endocardi-
tis in 4 (5.6%) patients and bioprosthetic failure in 4 (5.6%)
patients.
Associated procedures were: coronary artery bypass graft-
ing (n  22, 30.5%), mitral valve replacement (n  7,
9.7%), mitral valve repair (n  1, 1.4%) and tricuspid
annuloplasty (n  1, 1.4%). Patients undergoing concomi-
tant coronary artery bypass grafting had an average of 1.5 
0.2 grafts, and 59% (13/22) had a bypass with the left
internal mammary artery. The host annulus was measured
in all patients with a Hegar probe; mean measured annulus
size was 19.7  0.4 mm; diameter of annulus was then
indexed by patient BSA to obtain the patient annulus index
(PAI) (13); in our cohort PAI was 11.7  0.2 mm. Mean
valve size implanted was 22.0  0.8 mm and mean labeled
valve size/BSA was 1.2  0.2 cm/m2; for instance, 35
(48.6%) patients received a 21-mm valve and 37 (51.4%)
patients received a 23-mm valve. The implants were per-
formed as widely described (14). Contraindications for
using the stentless valve were extensive calcification of the
sinus aortic wall or an extremely thin aortic wall. The
average time on cardiopulmonary bypass was 118  72.1
min with a mean of 98  42.8 of aortic cross clamping.
All patients started, from the first postoperative day, a
regimen of a three-month treatment with warfarin sodium
(Coumadin, Du Pont Pharmaceuticals, Wilmington, Dela-
ware). The target international normalized ratio was 2.0 to
2.5.
Follow-up information was obtained from outpatient
clinic appointments; mean follow-up time was 41  14
months (range: 2 to 92 months). No patient was lost at
follow-up, which was 100% complete.
All data were collected according to the Society of
Thoracic Surgeons and the American Association for Tho-
racic Surgery guidelines for reporting mortality and mor-
bidity after aortic valvular surgery (15).
The investigational review board approved the study
protocol, and written informed consent was obtained from
all patients before enrollment.
Echocardiography. Echocardiographic imaging was per-
formed with a Hewlett Packard Sonos 5500 ultrasound
system with a 2.5 MHz transducer (Hewlett Packard,
Andover, Massachusetts) and recorded on VHS videotape
for subsequent review. The same technician (M. L. M.)
performed all exams with the supervision of a cardiologist
(G. M.). Imaging was performed in the early postoperative
period (before hospital discharge), six months after opera-
tion, one year after operation and yearly thereafter.
M-mode, two-dimensional, continuous pulsed-wave and
color Doppler were carried out, and standard views were
employed. Measurements of end systolic diameter, end
diastolic diameter, posterior wall thickness and septum
thickness were first made according to the recommenda-
tions of the American Society of Echocardiography using a
leading-edge-to-leading-edge convention (16). The pres-
ence of aortic regurgitation was quantified using color flow
Doppler (17); ratios of either percent diameter and percent
area of the jet to that of the left ventricular outflow tract
(LVOT) in the long- or short-axis views were calculated.
Aortic regurgitation was defined as trivial (grade I), mild
(grade II), moderate (grade III) or severe (grade IV) if the
ratio of the jet diameter to the LVOT diameter in the
long-axis view was 24%, 24% to 45%, 45% to 65% or
65%, respectively. Similarly, aortic regurgitation was de-
fined as trivial, mild, moderate or severe if the ratio of the jet
area to the LVOT area in the short-axis view was 4%, 4%
to 25%, 25% to 60%, 60%, respectively. Peak and mean
velocities in the LVOT (Vmax
LVOT [m/s] and Vmean
LVOT
[m/s]) and velocity-time integral (VTILVOT [cm]) were deter-
mined proximal to the valve using pulsed-wave Doppler. Peak
and mean velocities across the valve (Vmax
AV [m/s] and
Vmean
AV [m/s]) and VTI (VTILVOT [cm]) were calculated
using continuous wave Doppler through the aortic valve
(AV). The LVOT diameter was measured in midsystole
from the parasternal long-axis view. The LVOT cross-
sectional area (CSA) was calculated as: CSALVOT 
3.14·D2/4 (where D  diameter). All Doppler measure-
ments were averaged from 3 to 10 cardiac cycles in sinus
rhythm and in atrial fibrillation, respectively. Peak and
mean pressure gradients were calculated by applying the
modified Bernoulli equation (18); EOA was calculated
according the continuity equation (19). The EOA was
indexed by patient’s BSA and expressed as EOAI (cm/m2).
This index was used to detect mismatch between valve size
and patient’s BSA; according to Pibarot et al. (4), an EOAI
0.85 cm2/m2 was considered evidence of a mismatch,
which was defined as severe if EOAI was 0.65 cm/m2,
moderate if EOAI was 0.66 to 0.75 cm/m2 and mild if
EOAI was 0.76 to 0.85 cm/m2. Left ventricular mass
Abbreviations and Acronyms
ANOVA  analysis of variance
AV  aortic valve
AVR  aortic valve replacement
BSA  body surface area
CI  confidence interval
CLOB  Cryolife O’Brien
CSA  cross-sectional area
EOAI  effective orifice area index
LVM  left ventricular mass
LVMI  left ventricular mass index
LVOT  left ventricular outflow tract
MG  mean gradient
NYHA  New York Heart Association
PAI  patient annulus index
PPM  prosthesis-patient mismatch
RR  relative risk
RWT  relative wall thickness
VTI  velocity-time integral
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(LVM) was calculated employing measurements by Penn
convention (20); LVM was indexed by BSA and expressed
as left ventricular mass index (LVMI) (g/m2). End diastolic
wall thickness above the normal range of 0.6 to 1.1 cm
(mean: 0.9 cm) was considered hypertrophied (21). Left
ventricular ejection fraction was calculated by use of the
apical four-chamber view and the application of the modi-
fied Simpson rule method (22).
Statistical analysis. All data were analyzed with the SPSS
for Windows, release 8.0 (SPSS, Inc., Chicago, Illinois)
statistical package. Continuous data were presented as mean
 SD; discrete variables were given as percentages. Re-
peated analysis of variance (ANOVA) measures were used
to test the significance of changes of data at various points
of the study and the Sheffe´ post-hoc test was utilized for
multiple comparisons. The chi-square analysis or Fisher
exact test was used to compare categorical data. Death and
event-free survival estimates were calculated by the product-
limit method of Kaplan and Meier and reported with 95%
of confidence limit; the Mantel-Cox (log-rank) test was
used to test the hypothesis that there was no difference in
survival among groups.
Variables entered into a univariate model; significant and
borderline (p  0.1) factors were then reintroduced in a
multivariable model examining predictors of mismatch.
Results were expressed with the relative risk (RR) and 95%
of confidence interval (CI). Least squares linear correlation
was employed to study univariate relations between vari-
ables. In all cases a p value0.05 was considered significant.
RESULTS
Mortality, morbidity and functional status. There were
two early (30-day) deaths (2.7%); no death was directly valve
related as demonstrated by the postmortem examination.
Nonfatal complications occurred in 4.1% of cases: these
comprised one postoperative bleeding requiring re-
exploration, one sternal infection and one respiratory failure.
One patient died during follow-up. Seven-year actuarial
survival was 94.9  2.8% (0.8 patients/year; 95% CI, 0.4 to
1.2). Actuarial seven-year freedom from events were as
follows: reoperation (90.1  6.7%), structural valve deteri-
oration (96.1  3.4%), thromboembolism (100%),
anticoagulant-related hemorrhage (100%), endocarditis
(97.5  1.7%), all events (76.8  4.4%). At recent
follow-up all patients showed an improvement in functional
status; among 69 survivors, mean NYHA was 1.27  0.3
(p  0.001 vs. preoperatively). For instance, 50 (72.4%)
patients were in NYHA class I, 19 (27.6%) patients were in
class II and 0 patients were in class III or IV.
Echocardiographic/hemodynamic assessments. Hemo-
dynamic data are shown in Table 1. Mean transprosthetic
systolic gradient reduced significantly over time (p 0.001).
It showed at discharge a decrement of 47.1 mm Hg from
preoperative values (p  0.001); it reduced again at subse-
quent controls but without statistical significance. At dis-
charge, LVMI decreased by 26.5% (53 g/cm2 [p 
0.001]) from the baseline value. It reduced from 147 
39 g/cm2 to 119  26 g/cm2 (p  0.03) from discharge to
six months. At late control, LVMI was 97 14 g/cm2 (p
0.01 from the six-month value). Relative wall thickness
(RWT) decreased from 0.52  0.12 preoperatively to
0.41  0.1 at discharge (p  0.001), and it did not show
further significant changes. Basically, 6.1% (4/65), 6%
(3/50), 4.1% (1/24) and 0% (0/10) of patients still presented
features of concentric hypertrophy (RWT and LVMI both
elevated) at one-, three-, five- and seven-year controls,
respectively.
Incidence and impact of PPM. Patients also showed
statistically significant increase in EOAI (p  0.001). On
average, increases were 0.61  0.1 cm/m2 from baseline to
discharge (p  0.001), 0.33  0.1cm/m2 from discharge to
six-month control (p  0.04) and 0.2  0.1 cm/m2 (p 
0.3) from six-month study to the subsequent control. At
discharge, mean labeled size/BSA was 1.2  0.04 and
EOAI was 0.9 0.1 cm/m2 (p 0.001); this difference was
not significant up to the six-month control (p  NS). The
incidence of PPM at discharge was 22.2% (16/72); three
patients (18.7%) had a severe (EOAI  0.65 cm/m2), seven
Table 1. Echocardiographic Results
Preoperative
(n  72)
Discharge
(n  70)
6 Months
(n  69)
1 Year
(n  65)
3 Years
(n  50)
5 Years
(n  24)
7 Years
(n  10) *p Value
Vmax, m/s 4.9  0.3 2.1  0.3† 1.8  0.3‡ 1.7  0.4 1.6  0.3 1.5  0.2§ 1.5  0.2§  0.001
MG, mm Hg 57  12 10  3.3† 8  2.3 7  3.3 6  2.4 6  1.9 5  1.1  0.001
EOAI, cm2/m2 0.3  0.1 0.91  0.1† 1.11  0.1‡ 1.13  0.2 1.11  0.2 1.14  0.2 1.18  0.2  0.001
ESD, cm 4.0  1.1 3.9  0.1† 3.5  0.1‡ 3.4  0.6 3.4  0.8 3.4  0.6 3.2  0.5 0.01
EDD, cm 5.3  1.2 5.0  0.2† 4.9  0.2 4.6  0.8 4.6  1.1 4.7  0.7 4.5  0.5 0.01
LVMI, g/m2 200  54 147  39† 119  26‡ 114  19 108  22 104  18§ 97  14§  0.001
RWT, % 0.52  0.12 0.41  0.1† 0.44  0.1‡ 0.47  0.1 0.47  0.1 0.44  0.1 0.42  0.08  0.001
FS, % 0.23  0.06 0.23  0.05 0.28  0.02 0.26  0.02 0.26  0.1 0.27  0.1 0.28  0.1 NS
LVEF, % 48  16.4 44  12.2 55  18.3 51  21.1 52  20.3 54  19.7 56  22.3 NS
*p results of analysis of variance over time. †‡§Indicate a significant but different value from preoperatively, discharge and 6 months, respectively, at repeated analysis of variance
measures.
EDD  end diastolic diameter; EOAI  effective orifice area index; ESD  end systolic diameter; FS  fractional shortening; LVEF  left ventricular ejection fraction;
LVMI  left ventricular mass index; MG  mean transvalvular gradient; RWT  relative wall thickness; Vmax  peak transprosthetic velocity.
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(43.7%) had a moderate (EOAI 0.65 to 0.75 cm/m2) and
six (37.6%) had a mild (0.76 to 0.85 cm/m2) mismatch.
Table 2 shows preoperative characteristics of patients with
or without mismatch; patients with mismatch were older,
prevalently women, received a smaller valve size, had a
smaller BSA and a smaller PAI; furthermore, they had
higher baseline mean gradient (MG) and LVMI. Determi-
nants of mismatch at univariate analysis (Table 3) resulted
in being female gender, BSA, age and PAI. At multivariable
analysis, gender (RR: 7.08; 95% CI: 2.24 to 12.4, p 
0.001), age (RR: 1.09; 95% CI: 0.97 to 1.23, p  0.015),
BSA (RR: 9.76; 95% CI: 5.26 to 14.26, p 0.001) and PAI
(RR: 6.9; 95% CI: 2.8 to 11.2, p  0.001) were significant
factors independently affecting the early occurrence of
PPM. In contrast, labeled valve size (RR: 1.04; 95% CI:
0.96 to 1.3, p  0.39) and labeled valve size/patient’s BSA
(RR: 1.09; 95% CI: 0.97to 1.25, p  0.33) resulted in not
being significant. At six months two patients (16.6%)
belonging to the 21-mm group and one to the 23-mm
group (1.7%) still showed echocardiographic evidence of
mismatch. The incidence of mismatch was 0% at subse-
quent controls. Patients with “transient” mismatch had
higher mean gradients at discharge (13.3 vs. 7.1 mm Hg,
p  0.01) and six months (9.1 vs. 6.4 mm Hg, p  0.01).
At one-year (8.6 vs. 6.5 mm Hg, p  NS), three-year
(6.1 vs. 5.9 mm Hg, p NS), five-year (6.3 vs. 5.7 mm Hg,
p  NS) and seven-year (6.4 vs. 5.1, p  NS) studies, no
difference in MG was detected between patients with or
without mismatch. The LVMI reduced over time in both
groups (Table 4). It decreased by 23.4% and 34.1% at
discharge (pNS), by 11.9% and 18.9% at six months (p
NS), by 13.8% and 8.8% at one year (p  NS), by 14.8%
and 0.3% at five years (p  0.001) and by 4.5% and 9.5% at
seven years (p  NS) in patients with or without mismatch,
respectively. At one-way ANOVA, postoperative EOAI
0.85 was a borderline factor associated with a greater
Table 2. Preoperative Data: Patients With or Without Evidence of Mismatch
EOAI < 0.85 cm2/m2 EOAI > 0.85 cm2/m2 p Value
Age, yrs 77.2  10 67.9  9 0.01
Female gender 93.7% (15/16) 67.8% (38/56) 0.01
Valve size
Mean, mm 21.3  0.1 2.2  0.3 0.03
21 mm 13 (81.2%) 22 (39.2%)
23 mm 3 (18.8%) 34 (60.8%)
PAI, mm 10.7  0.08 12.0  0.1  0.001
Body surface area 1.62  0.1 1.74  0.1 0.001
NYHA III 93.7% (15/16) 92.8% (52/56) NS
Pathology NS
Stenosis 62.5% (10/16) 62.5% (35/56)
Insufficiency 12.5% (2/16) 10.8% (6/56)
Mixed 25.0% (4/16) 26.7% (15/56)
CAD 25.0% (4/16) 32.1% (18/56) NS
MVD 12.5% (2/16) 10.7% (6/56) NS
MG, mm Hg 65  14 50.2  10 0.01
LVMI, g/m2 214.6  62 186.4  46 0.03
LVEF, % 47.7  14.6 48.7  17.1 NS
CAD  (associated) coronary artery disease; EOAI  effective orifice area index; LVEF  left ventricular ejection fraction;
LVMI  left ventricular mass index; MG  mean transvalvular gradient; MVD  (associated) mitral valve disease; NYHA 
New York Heart Association functional class; PAI  patient’s annulus index.
Table 3. Predictors of PPM at Univariate Analysis
Variable
Relative
Risk 95% CI p Value
Age  70 yrs 1.4 0.6–2.3 0.02
Female gender 7.1 5.3–13.9  0.001
BSA  1.7 m2 6.3 5.8–11.8 0.01
Aortic stenosis 1.1 0.6–1.6 NS
NYHA class  III 0.9 0.7–1.1 NS
Labeled valve size  23 mm 1.4 0.3–4.1 NS
Labeled valve size/BSA  1.3 cm/m2 1.0 0.9–11 NS
PAI  11 mm 7.6 6.2–18.3  0.001
MG  40 mm Hg 2.3 1.6–3.0 NS
Vmax  4 m/s 1.8 1.4–2.2 NS
LVMI  180 g/m2 0.7 0.4–1.3 NS
BSA body surface area; LVMI (preoperative) left ventricular mass index; MG (preoperative) mean transvalvular gradient;
NYHA  New York Heart Association functional class; PAI  patient’s annulus index; PPM  prosthesis-patient mismatch;
Vmax  (preoperative) peak transprosthetic velocity.
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LVMI (p  0.08). At multivariable analysis, reduction in
LVMI was not significantly affected by the presence of
PPM (RR: 1.38, 95% CI: 0.31 to 2.57, p  0.13).
DISCUSSION
Aortic valve replacement in the small aortic root has been
reported to be associated with obstruction of left ventricular
output. It predominantly occurs in small aortic roots, which
require the use of small prostheses resulting in higher
transvalvular gradients (23). Since Rahimtoola (5), in 1978,
stated, “mismatch can be considered to be present when the
effective prosthetic valve area, after insertion into the pa-
tient, is less than that of a normal human valve,” PPM has
been recognized by the American Society of Thoracic
Surgeons, and it has been identified as a nonstructural
dysfunction (13). It is still uncertain if PPM may affect
postoperative mortality; previous studies (1,24) have dem-
onstrated that mortality was higher in patients receiving a
small (21 mm) aortic prosthesis; nonetheless, two previous
reports of a relatively small number of patients failed to
show a negative impact of mismatch on survival (3,4). In a
recent study, Rao et al. (25) reported the in vitro calculated
EOA/BSA 0.75 cm2/m2 to have a strong impact on
survival. Many studies have demonstrated that all prosthetic
valves are at least mildly stenotic and that they result in high
postoperative transprosthetic gradients despite normal valve
function (26). Particularly, stented valves lead to a non-
physiological flow pattern and do not achieve complete
abolition of transvalvular gradients because of the obstruc-
tive effects of the prosthetic valve stents and sewing ring
(27). Moreover, allografts and autografts represent an ideal
substitute, but their use is restricted because of a limited
availability, and there is still no agreement about annulus
enlarging techniques, considered by some as safe and by
others to significantly increase morbidity and mortality after
AVR (28,29). Unstented valves could represent, theoreti-
cally, a resolution to the problem (30) because they generally
provide a larger EOA in relation to the patient’s BSA, as
compared with stented bioprostheses (31). Nonetheless, the
EOA of a stentless valve inserted within the patient’s aorta
remains somewhat smaller than that of the corresponding
native valve, and differences in valve sizing among manu-
facturers make comparisons between different prostheses
almost impossible. Christhakis et al. (32) demonstrated that
internal prosthesis diameters are 4 mm smaller than external
ones, which corresponds to the manufacturer’s size. Rao et
al. (33) showed stentless and stented bioprostheses to have
similar hemodynamic profiles when the comparison is
adjusted to reflect true measured dimensions (33). We
present clinical and hemodynamic results of the perfor-
mance of CLOB suprannular stentless valves (34) in pa-
tients with small aortic roots. The theoretically great advan-
tage of the CLOB over other stentless valves is the
suprannular design; in its correct position the prosthetic
valve is sutured to the aortic wall, above the annulus, thus
allowing a larger effective flow area for any given measured
host annulus. Certainly, following our prosthesis selection
criteria and annulus measurement method, all patients have
received a valve larger than they would receive if a stented or
an intrannular stentless had been chosen. For instance, in
our experience, we oversized by one in the majority of
patients, by two in 10 and by three in two patients. Those
two patients had a very small annulus (19 mm), and
one of them was a young man with a large BSA (1.75)
who would have been expected to have a PPM. At the latest
control, both patients presented an adequate EOAI
(1.12 cm/m2 and 1.11 cm/m2, respectively).
Incidence of PPM. In our series 16 patients had evidence
of a “transient” mismatch early postoperatively; this inci-
dence is not negligible, but it can be justified by a very small
PAI in our population (11.7  0.2 mm). However, in
contrast with other authors who, in studies not only re-
stricted to patients with a small aortic root, reported a 19%
to 29% incidence of PPM at one year in other intrannular
stentless bioprostheses (30,35), in our series no patient had
evidence of “permanent” PPM at one year and at subsequent
controls. These remarkable results may have important
clinical implications and makes the suprannular CLOB
valve an ideal substitute for patients with small aortic roots.
To date, the only biological substitutes that provide com-
parable results in terms of PPM prevention are the pulmo-
nary autografts (Ross operation) and the aortic homografts
(35). However, how can an increment in EOA in a fixed
valve be explained? This had been previously explained with
a progressive regression of perivalvular edema/hematoma
occurring early postoperatively within the patient’s aortic
root after stentless AVR. We can speculate that a thin-
walled stentless valve, made without any prosthetic material,
is associated with a more distensible aortic sinus and allows
a more dynamic aortic root function than other prostheses,
thus achieving a higher systolic flow and a greater EOA,
which is a function of systolic flow (36,37). Dumesnil et al.
Table 4. Changes in LVMI (g/m2)
Discharge 6 Months 1 Year 5 Years 7 Years
EOAI  0.85 cm2 164.3  45.2* 144.6  26.3 124.6  5.0‡ 106  14.4§ 101.3  12.1
EOAI  0.85 cm2 138.6  36.4* 112.4  25.2† 102.4  4.3 102.1  13.8 92.3  14.1
p 0.01 0.01 0.03 NS NS
*,†,‡,§Indicate a significant different value from preoperatively, discharge and 6 months, respectively, at repeated analysis of
variance measures. p  significance at unpaired t test.
EOAI  effective orifice area index; LVMI  left ventricular mass index.
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(38) demonstrated that, for equal volume load, a hypertro-
phied heart has a higher ejection fraction than a normal
heart and that this will translate into an higher transvalvular
velocity, and Del Rizzo et al. (39) showed a strong linear
relation between gradients and transvalvular velocities; in
contrast, he failed to demonstrate a correlation between
gradients and LVOT velocities or CSALVOT. Thus, hemo-
dynamic and geometric changes of the left ventricle, and, in
particular, regression of left ventricular hypertrophy, could
play an important role causing a reduction in transvalvular
velocity and, consequently, increasing EOA, which is in-
versely related to the transvalvular velocity (20).
Hemodynamic repercussions of PPM. In our small co-
hort, CLOB valve showed excellent hemodynamics with
low postoperative gradients and early regression of left
ventricular hypertrophy. “Transient” PPM mismatch did
not have negative repercussions on the patient’s hemody-
namic status. Mean gradient reduced independently from an
EOAI 0.85 cm/m2. In our analysis, female gender, BSA,
age and PAI resulted in significantly affecting the occur-
rence of postoperative mismatch. In contrast, and according
to Pibarot et al. (40), labeled valve size and labeled valve size
indexed to the patient’s BSA did not affect the incidence of
mismatch. Valve pathology (stenosis) and NYHA func-
tional class resulted in not being significant. Moreover,
differently from Del Rizzo et al. (41), we failed to show a
relation between EOAI and the extent of LVM regression.
Finally, left ventricular ejection fraction did not differ in
patients with and without mismatch (p  NS).
Study limitations. Our study presents some strong limita-
tions, which have to be pointed out: 1) the number of
patients was rather small; 2) the limited number of events
limited the strength of analysis; 3) the retrospective nature
limits the significance of the study; 4) exams were per-
formed at rest, and no information about parameters mea-
sured under stress was given; 5) in our cohort the average
BSA is relatively small; it is, therefore, possible that the
incidence and severity of mismatch with the CLOB valve
will be more frequent in populations with larger body
surface areas (i.e., North American populations); and 6) the
CLOB bioprosthesis was not compared with other stented
or stentless valves.
Larger studies, comparing different types of valves
(stented, intrannular stentless and suprannular stentless) on
the basis of the patient’s true annulus index are necessary to
confirm if the oversizing procedure really allows better
hemodynamics to be achieved and, in this way, if a supran-
nular stentless valves could represent an optimal choice for
the management of the small aortic annulus.
Conclusions. Stentless AVR with a suprannular CLOB
valve in patients with small aortic roots yielded excellent
hemodynamics. Although all patients had a relatively small
aortic annulus, none of them had PPM one year after
operation. Even with the above-mentioned limitations, this
study demonstrates that PPM can be completely avoided
when using the CLOB valve. The superior hemodynamics
of this stentless valve is likely to be related to its suprannular
design.
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